New Delhi: As the demand for Covid-19 vaccines rise exponentially, Biological-E’s RBD protein sub-unit vaccine Corbevax might be probably the most inexpensive vaccine in India as soon as it will get emergency use approval.
As per a report, two doses of Corbevax might even be priced under Rs 400, which is kind of much less as in comparison with the opposite Covid vaccines.
Covishield manufactured by the Serum Institute of India (SII) is priced at Rs 300 per dose for the state governments and Rs 600 per dose for the personal hospitals whereas Bharat Biotech’s Covaxin is promoting for Rs 400 and Rs 1,200 respectively.
On the opposite hand, Russia’s Sputnik V has been priced at Rs 995 per jab.
READ: Third Wave Scare | 24,000 Children Test Positive For Covid-19 In Andhra Pradesh In Two Weeks
Earlier this week, the Union Health Ministry had finalised preparations with Hyderabad-based vaccine producer Biological-E to order 30 crore of Covid-19 vaccine doses.
These vaccine doses will likely be manufactured and stockpiled by M/s Biological-E from August-December 2021. For this function, the Union Ministry of Health could be making an advance cost of Rs. 1500 crore to M/s Biological-E.
The Covid-19 vaccine of Biological-E is at present present process Phase-3 medical trial after displaying promising leads to Phase 1 and a pair of medical trials. The vaccine being developed by Biological-E is a RBD protein sub-unit vaccine and is prone to be obtainable within the subsequent few months.
The proposal of M/s Biological-E was examined and really useful for approval after due diligence by National Expert Group on Vaccine Administration for COVID-19 (NEGVAC).
The association with M/s Biological-E is a part of the broader endeavour of Government of India to encourage indigenous vaccine producers by offering them assist in Research and Development (R&D) and in addition monetary assist.
“Biological-E COVID Vaccine candidate has been supported by Government of India from Preclinical stage to Phase-3 studies. Department of Biotechnology has not only provided financial assistance in terms of grant-in-aid of over Rs 100 cr but has also partnered with Biological-E to conduct all animal challenge and assay studies through its Research Institute Translational Health Science Technology Institute (THSTI), Faridabad,” the Union Health Ministry stated in a launch earlier on June 3.
“This has been undertaken as part of Government of India’s ‘Mission COVID Suraksha- the Indian COVID-19 Vaccine Development Mission’ which was launched to reinforce and accelerate COVID-19 vaccine development efforts as part of the third stimulus package, Atmanirbhar 3.0.,” the ministry added.
The Union Health Ministry additional stated the mission goals to deliver to the residents a protected, efficacious, inexpensive and accessible Covid-19 Vaccine.
“The mission is supporting development of 5-6 COVID-19 vaccine candidates. Some of these are now closer to licensure and introduction in public health systems. It has not just accelerated COVID-19 Vaccine development efforts, but also fostered a robust end-to-end vaccine development ecosystem in the country that will be available for other on-going and future research and developmental activities for other vaccines,” the ministry added.
Check out under Health Tools-
Calculate Your Body Mass Index ( BMI )
